(a)
(b)
(c)
(d)
Figure 5: Acylated ghrelin (AG) inhibits p53 levels and activity, cytochrome C release, and activation of cleaved caspase-3 and downregulates PUMA in control and cisplatin- (Cis-) treated cultured human chemosensitive ovarian cancer cells (A2780). Cells were grown in DMEM/F12 media containing AG ghrelin (1 nM) for 24 hours, then transferred to a medium containing the vehicle for the next 72 hours. For Cis treatment, cells were grown in the same medium containing Cis (10 μM) for 72 hours. In addition, AG and Cis-treated cells were also preincubated with 10 μM ghrelin receptor antagonist, [D-Lys3]-GHRP-6, and/or 20 μM of the PI3K inhibitor, LY294002. Control cells were grown in the presence equivalent volume of normal saline. Results are shown as the of experiments. a: vs control (lane 1), b: vs AG (lane 2), c: vs AG+LY294002 (lane 3), d: vs Cis (lane 4), e: vs AG+Cis (lane 5). Lane 6: Cis+AG+LY294002 and lane 7: Cis+AG+[D-Lys3]-GHRP.